Hypertension in chronic glomerulonephritis

Electrolyte and Blood Pressure

Volumn 13, Issue 2, 2015, Pages 41-45

  Ihm, Chun Gyoo ^a  

^a Kyung Hee University College of Medicine   (South Korea)

Author keywords

Chronic glomerulonephritis; RAAS blockade; Volume dependent

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PROTEIN;

BLOOD PRESSURE REGULATION; CHRONIC GLOMERULONEPHRITIS; HIGH RISK POPULATION; HUMAN; HYPERTENSION; PATHOPHYSIOLOGY; PREVALENCE; PROTEIN URINE LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 84957055243     PISSN: 17385997     EISSN: 20929935     Source Type: Journal    
DOI: 10.5049/EBP.2015.13.2.41     Document Type: Review

References (27)

1. Nachman PH, Jennette JC, Falk RJ: Primary glomerular disease. In: The kidney, 10th ed., edited by Brenner BM, Rector Jr FC, Philadelphia, Saunders, 2011, p1101-1191
2. Orofino L, Quereda C, Lamas S, Orte L, Gonzalo A, Mampaso F, et al.: Hypertension in primary chronic glomerulonephritis: analysis of 288 biopsied patients. Nephron 45:22-26, 1987
3. Csiky B, Kovács T, Wágner L, Vass T, Nagy J: Ambulatory blood pressure monitoring and progression in patients with IgA nephropathy. Nephrol Dial Transplant 14: 86-90, 1999
4. Kaplan NM: Renal parenchymal hypertension. In: Clinical Hypertension. 7th ed., Baltimore, Williams & Wilkins, 1998, p281-299
5. Joles JA, and Koomans HA: Causes and consequences of increased sympathetic activity in renal disease. Hypertension 2004;43:699-706
6. Valvo E, Gammaro L, Bedogna V, Giorgetti PG, Tonon M, Panzetta GO, et al.: Hypertension in primary immunoglobulin A nephropathy (Berger's disease): hemodynamic alterations and mechanisms. See comment in PubMed Commons belowNephron 45:219-223, 1987
7. Ikee R, Kobayashi S, Saigusa T, Namikoshi T, Yamada M, Hemmi N, et al.: Impact of hypertension and hypertension-related vascular lesions in IgA nephropathy. Hypertens Res 29:15-22, 2006
8. Bazzi C, Stivali G, Rachele G, Rizza V, Casellato D, Nangaku M: Arteriolar hyalinosis and arterial hypertension as possible surrogate markers of reduced interstitial blood flow and hypoxia in glomerulonephritis. Nephrology 20:11-17, 2015
9. Konishi Y, Okada N, Okamura M, Morikawa T, Okumura M, Yoshioka K, et al.: Sodium sensitivity of blood pressure appearing before hypertension and related to histological damage in immunoglobulin a nephropathy. See comment in PubMed Commons belowHypertension 38: 81-85, 2001
10. Jang WS, Jeong KH, Moon JY, Lee SH, Cho JH, Lee TW, et al.: Relationship between glomerulomegaly and clinicopathologic findings in IgA nephropathy. Clin Nephrol 78:470-477, 2012
11. Kim YG, Song SB, Lee SH, Moon JY, Jeong KH, Lee TW, et al.: Urinary angiotensinogen as a predictive marker in patients with immunoglobulin A nephropathy. Clin Exp Nephrol 15:720-726, 2011
12. Lee HJ, Choi SY, Jeong KH, Sung JY, Moon SK, Moon JY, et al.: Association of C1q deposition with renal outcomes in IgA nephropathy. Clin Nephrol 80:98-104, 2013
13. Nishiyama A, Konishi Y, Ohashi N, Morikawa T, Urushihara M, Maeda I, et al.: Urnary angiotensinogen reflects the activity of intrarenal renin-angiotensin system in patients with IgA nephropathy. See comment in PubMed Commons belowNephrol Dial Transplant 26:170-177, 2011
14. Kobori H, Katsurada A, Ozawa Y, Satou R, Miyata K, Hase N, et al.: Enhanced intrarenal oxidative stress and angiotensinogen in IgA nephropathy patients. See comment in PubMed Commons belowBiochem Biophys Res Commun 358:156-163, 2007
15. Konishi Y, Nishiyama A, Morikawa T, Kitabayashi C, Shibata M, Hamada M, et al.: Relationship between urinary angiotensinogen and salt sensitivity of blood pressure in patients with IgA nephropathy. Hypertension 58:205-211, 2011
16. Kim SM, Chin HJ, Oh YK, Kim YS, Kim S, Lim CS: Blood pressure-related genes and the progression of IgA nephropathy. Nephron Clin Pract 113:c301-308, 2009
17. Shinzawa M, Yamamoto R, Nagasawa Y, Shoji T, Obi Y, Namba T, et al.: Gene polymorphisms contributing to hypertension in immunoglobulin A nephropathy. Clin Exp Nephrol 16:250-258, 2012
18. Park M, Jeong K, Moon J, Lee T, Ihm C, Lee S: The Treatment Response to Angiotensin Receptor Blocker According to ACE Gene Polymorphism in Patients with IgA Nephropathy. Korean J Nephrol 27:13-19, 2008
19. See comment in PubMed Commons belowStevens PE, Levin A; Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members: Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 158:825-830, 2013
20. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al.: 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311: 507-20, 2014
21. ESH/ESC Task Force for the Management of Arterial Hypertension: 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens 31:1925-1938, 2013
22. ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, et al.: Effects of intensive blood-pressure control in type 2 diabetes mellitus. See comment in PubMed Commons belowN Engl J Med 362:1575-1585, 2010
23. See comment in PubMed Commons belowSchrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI, et al.: Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med 371:2255-2266, 2014
24. SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al.: A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 373:2103-2116, 2015
25. Nelson RG, Tuttle KR: The new KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and CKD. Blood Purif 25:112-114, 2007
26. Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al.: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, doubleblind, controlled trial. Lancet 372:547-553, 2008
27. Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, et al.: Renal outcomes with different fixeddose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 375:1173-1181, 2010